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The individual response to standard doses of drugs has a large variability depending on intrinsic
factors (age, sex, and disease states) and/or extrinsic factors (diet, chemical exposures from
the environment). The influence of these factors on drug responses has therefore to be taken
into consideration when making decisions on treatment regimes (Thummel and Lin, 2014).
Nonetheless, the taking into account of these factors limits, but does not eliminate, the high
degree of interindividual variability in terms of efficacy or fatal adverse reactions. The individual
genetic background, explains part of the different pharmacokinetic and pharmacodynamic drug
responses both in term of efficacy and toxicity (Hertz and McLeod, 2013). Evidence indicates
that genetic variations account for an estimated 20–40% of inter-individual differences in drug
metabolism and response (Karczewski et al., 2012). The commonest genetic variations are single
nucleotide polymorphisms (SNPs), representing approximately 90% of all human genetic variations
and occurring every 100–300 base pairs (Crews et al., 2012). Some of these polymorphisms have
been identified for many proteins including enzymes, drug receptors, transporters, and targets
of the commonest drugs. These polymorphisms can cause alterations in the amount, structure,
binding, and/or function of these proteins, influencing how drugs interact with them (Ma et al.,
2012; Patel et al., 2013). The study of these genetic variants and their role in improving drug efficacy
and reducing side effects, termed pharmacogenetics, is now established in the clinical practice for
many drugs including abacavir, irinotecan, and 6 mercaptopurines (Ingelman-Sundberg, 2008;
Wang et al., 2011). To facilitate an appropriate clinical implementation of pharmacogenetics,
guidelines have been published by the Clinical Pharmacogenetics Implementation Consortium
(CPIC) and the Dutch Pharmacogenetics Working Group (DPWG). The aim of these guidelines
as they clearly state is to facilitate translation of the genetic laboratory test results into prescribing
decisions for specific drugs, or class of drugs, such as vitamin K antagonist, tricyclic antidepressants
(Johnson et al., 2011; Caudle et al., 2013; Hicks et al., 2013). So far, several techniques have
been described to detect specific SNPs, with the Sanger Sequencing, the Denaturing Gradient
Gel Electrophoresis (DGGE), the Single Strand Conformational Polymorphism analysis (SSCP),
the Pyrosequencing and Sequenom being the most widely employed. Recently also techniques
of high-throughput screening and for large-scale characterization of SNPs have been developed;
these platforms, however, are expensive, not flexible and not of practical use for small to medium
size laboratories. More user-friendly, SNPs detection methods for pharmacogenetic tests are based
on PCR amplification, in conjunction with an appropriate probe technology (real-time PCR) as
TaqMan, Scorpion and SimpleProbe R©. Among these, SimpleProbe R© appears of particular interest.
SimpleProbe format is composed of one hybridization probe, labeled with a fluorophore; this
oligonucleotide is designed spanning the variant of interest, but does not participate into the
amplification process. Once hybridized to its target sequence, the SimpleProbe probe releases more
fluorescence than when not hybridized. Changes in fluorescence that are exclusively based on the
probe hybridization status are detected by melting curve analyses. Any mismatch positioned under
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the SimpleProbe R© will reduce the hydrogen-bonds, hence the
melting temperature, thus enabling analysis of polymorphisms.
Diverse variations destabilize the hydrogen-bonds differently,
usually yielding different and specific melting points, thus
making it possible to identify polymorphisms tightly close to the
intended variant, giving it potential advantages over competing
technologies.
Here, we describe the advantages of real-time PCR assays for
the detection of three SNPs selected for their involvement in
DPD and UGT1A1 enzymes regulations (Falvella et al., 2015).
This SNP detection is based on LightCycler Technology with
SimpleProbe R© probes (LightSNiP assays); it designed by TIB
Molbiol (Berlin, Germany) and is a validated Real Time PCR
method used in many areas of molecular diagnostics. From
amplification and detection with specific probes by melting curve
analysis, it is possible to obtain a visual discrimination of normal
and variant alleles in the homozygous and heterozygous status.
When selecting the most appropriate technique for a analysis of a
given genotype, few general considerations should be taken into
account such as correct detection, simplicity in the technology
and reproducibility.
Example 1. rs8175347 (UGT1A1∗28)
UGTs are important determinants of drug responses influencing
glucuronidation (Rowland et al., 2013); the best known of them
is the UGT1A1 gene. A common promoter (TA)n polymorphism
(UGT1A1∗28, 7TA repeats) significantly decreases UGT1A1
gene transcription, leading to reduced glucuronidation, in turn
increasing toxicity of SN-38, the active metabolite of irinotecan
(Innocenti et al., 2014). Because of this, UGT1A1∗28 has now
become a biomarker of neutropaenia, and its analysis is inserted
into the irinotecan package. Two others alleles in the UGT1A1
promoter region, UGT1A1∗36 (TA)5 and UGT1A1∗37 (TA)8,
have been associated to altered enzyme function and may
be detected by the hybridization probes (von Ahsen et al.,
2000); however their occur almost exclusively in populations of
African origin (Beutler et al., 1998). In addition, genotyping of
UGT1A1∗28 by LightSNiP can also identify a very rare allele
positioned in close proximity. As shown in Figure 1A (upper
panel), the sample indicated by the arrow presented a different
temperature profile in one of the two peaks obtained: while
the melting peak of 52.97◦C corresponded to the UGT1A1∗1
common allele (6TA repeats) we found one peak at 48.09◦C,
different from the expected peak at 53.72◦C for UGT1A1∗28,
unmasking the existence of another polymorphism. By direct
sequencing, we were able to identify the presence of the UGT1A1
“C” allele in heterozygosis in c.-64 position (rs873478 G>C)
(Figure 1A, lower panel).
Example 2. rs3918290 (DPYD∗2A)
Genetic variations in DPYD have been identified as a major
contributor to Dihydropyrimidine dehydrogenase (DPD)
deficiency. The most studied DPYD variation, catalytically
inactive, is the ∗2A (rs3918290) leading to reduced clearance of
5-fluorouracil (5-FU) and increased frequency of severe toxicity
(Johnson et al., 2002). Genotyping of the DPYD∗2A variant by
LightSNiP assay may be accompanied by unusual types of curves
in the correspondence of the expected peak of the common allele
(49.37◦C). In particular, melting curve analyses displayed either a
“baggy” (Figure 1B, upper panel) or a “bulge” (Figure 1C, upper
panel) curve. These melting profiles suggest that one or more
bases remain unpaired. The sequencing analysis confirmed the
presence of an as yet undetected polymorphisms. Particularly,
the “baggy” curve represents the DPYD c.1896 (rs17376848)
variant allele (Figure 1B, lower panel) and the “bulge” curve the
DPYD c.1905 (rs3918289) variant allele (Figure 1C, lower panel),
both in heterozygosis.
Example 3. rs895819 (miR-27a)
DPD expression may be regulated at the post-transcriptional
level. Recent data have suggested that mapping of rs895819 in
miR-27a may be useful to determine 5-FU sensitivity, since it has
been associated with a reduced DPD enzyme activity (Offer et al.,
2014). As expected, genotyping of rs895819 showed a melting
peak at 62.98◦C for the common allele and at 70.34◦C for the
variant allele. As shown in Figure 1D (upper panel), the sample
indicated by an arrow in correspondence to the expected peak
at 62.98◦C presented a “bulge” melting curve. Also in this case
the sequencing analysis revealed the presence in heterozygosis
of rs11671784, another polymorphism tightly close to the one in
study (Figure 1D, lower panel).
Clinical Utility
The predictive power of pharmacogenetic tests depends on the
contribution of the genetic polymorphisms on the expression
and/or function of the gene involved in the pharmacological
response, the frequency of the variants tested and the presence
of alternative pharmacokinetic pathway(s). To date, some
anticancer drugs approved by the US FDA, including irinotecan
and 5-fluorouracil, require a germline pharmacogenetic testing
prior to their administration, as indicated in their prescription
drug labeling. This report highlights that how pharmacogenetic
testing is carried out is critical since the choice of a specific
method may be instrumental in unmasking factors that influence
the response to these drugs and that go unnoticed with other
methods.
Concerning irinotecan, polymorphisms within UGT1A1 have
been shown to reduce glucuronidation of the active metabolite
SN-38, thus leading to an increase in its circulating levels and an
increased risk of severe neutropaenia; the UGT1A1∗28 genotype
can thus be used to individualize dosing of irinotecan (Innocenti
et al., 2014). Since polymorphisms in the promoter region of
the coding gene have been reported associated to transcriptional
regulation, a genotyping method able to detect the existence of
SNPs close to the promoter functional region is of choice. The
rs873478 (c.-64G>C) polymorphism is close to the UGT1A1∗28
allele; its allele frequencies is 1% globally, reaching as high as
4% in East Asian Individuals (1000 genomes). The role in gene
expression of rs873478, located 11 base pairs upstream the TATA
box, is still not known (Yea et al., 2008); thus, methods that detect
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FIGURE 1 | Genotyping and sequencing of three SNPs: UGT1A1
sequence around c.-64G>C (A), DPYD sequence around
rs3918290 (B,C), miR-27a rs895819 (D). In the melting curve
analysis obtained by LightSNiP probe during genotyping, the common
genotype (wild-type) are indicated by dot and heterozygous by
dash-dot style, while the arrows indicate samples of rare genotype. In
the panel of direct sequencing, letters “R” and “n” indicate additional
polymorphisms.
it alongside the otherUGT1A1∗28 polymorphism are useful tools
to establish its clinical relevance.
Genetic variations in the DPD gene (DPYD), coding for a key
enzyme involved in the catabolic pathways of fluoropyrimidines,
have been recognized as major contributors to enzyme deficiency
and fluoropyrimidines-associated toxicity. Some polymorphisms
in DPYD gene have been reported in association with
reduced enzyme activity. In particular, the genotyping of
c.1905+ 1G > A (∗2A), c.1679T > G, and c.2846A > T is
recommended in the clinical practice to prevent severe toxicity;
they however explain only a small percentage of the toxicity
due to low allelic frequency (Johnson et al., 2002; Morel et al.,
2006). Other DPYD variants linked to fluoropyrimidines toxicity
have been described, including the DPYD c.1896 variant close
to DPYD ∗2A (Teh et al., 2013). The frequency of this variant
is high, reaching 6% in the global population, and its detection
has therefore acquired clinical significance. The SimpleProbe R©
technology allows the identification in DPYD∗2A of the c.1896
variant alongside the other ones. A new genotyping assay,
developed specifically for a DPYD c.1896 confirmed what was
seen with sequencing and “baggy” curve.
Intra-individual difference in DPD expression may be due
also to epigenetic factors. miR-27a and miR-27b repress DPD
expression and therefore are important in cellular sensitivity to
5-fluorouracil (Offer et al., 2014); rs895819 maps in the coding
region of the hsa-mir-27a hairpin and is quite common being
present in up to 35% of the global population (1000 genomes).
The variant allele at rs895819 results in a loop region larger than
the common hairpin and therefore more effectively processed,
thus enhancing mature miR-27a expression (Offer et al., 2014).
When we genotyped rs895819 by LightSNiP we were able to
detect also rs11671784, another polymorphism very close to
rs895819. The miR-27a rs11671784 polymorphism is located at
a distance of only 4 nucleotides and represents a rare variant,
consisting of a G >A nucleotide substitution that results in a
change from a G:C complementary pair to a G:Umismatch in the
stem region of miR-27a precursor (Yang et al., 2014). This variant
has been reported to impair the maturation of miR-27a, resulting
in a reduced expression of mature miR-27a and reduced gastric
cancer risk (Yang et al., 2014). A genotyping assay able to detect
at the same time rs895819 and the rare variant rs11671784 is thus
a real clinical need. In this respect it is important to emphasize
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that the TaqMan allelic discrimination assay does not detect this
variant (Yang and Burwinkel, 2012).
The three examples described highlight also some
methodological aspects relevant in the clinical perspective.
The “ideal” genotyping method needs to meet several quality
specifications. In particular, the method has to be easily and
quickly developable by the DNA sequence, with a low cost
of assay development for both reagents and time spent for
optimization, and make use of a reaction capable of amplifying
correctly also non-optimal DNA samples. It also has to be
automated and with minimal hands-on operation, with simple
data analysis and a flexible and scalable reaction format (Kwok,
2001).
Here we show that, at least for the specific genes and
polymorphisms we analyzed, LightSNiPs probes are a highly
sensitive and rapid tool for SNP genotyping because they
readily identify both frequent and rare variant alleles with a
single short probe. Additionally, the LightSNiP assay detects
other polymorphisms under the hybridization probe and in
the proximity of the intended SNP, through the generation
of abnormal or unexpected melting curve point. Once these
are characterized, as we did, by sequencing analysis their
interpretation in subsequent tests becomes immediate and thus
of diagnostic usefulness. We do not imply to establish a
superiority of LightSNiP vs. other methods, for which, we would
have had to carry out a full comparison analysis; we just highlight
a good intrinsic quality of the genotyping-method significant
for routine diagnostic pharmacogenetics activity. Based on the
features and the ease of use of SimpleProbe R© technology,
we suggest that the LightSNiP assay is a good strategy for
pharmacogenetics analysis to provide the clinician a correct
results in a short time.
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